ArticleBioMed research international2014
Preliminary clinical experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT imaging in prostate cancer patients.
Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The Diagnostic Role ofFrontiers in oncology · 2021Pooled it
- [European journal of nuclear medicine and molecular imaging · 2020Guideline
- The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis.World journal of urology · 2019Pooled it
- Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.The Journal of urology · 2023Trial
- Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.Clinical nuclear medicine · 2017Trial
- Review
- The Integration of Metabolomics with Other Omics: Insights into Understanding Prostate Cancer.Metabolites · 2022Review
- 18F-Fluciclovine Positron Emission Tomography in Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis.Diagnostics (Basel, Switzerland) · 2021Review
- Diagnostic performance ofAmerican journal of nuclear medicine and molecular imaging · 2021Article
- Review
- 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment.Clinical nuclear medicine · 2019Article
- Fluciclovine positron emission tomography in the setting of biochemical recurrence following local therapy of prostate cancer.Translational andrology and urology · 2018Review
- Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer.Translational andrology and urology · 2018Review
- Update onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Review
- Positron emission tomography (PET) in primary prostate cancer staging and risk assessment.Translational andrology and urology · 2017Review
- PET Tracers Beyond FDG in Prostate Cancer.Seminars in nuclear medicine · 2016Review
- Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.European journal of nuclear medicine and molecular imaging · 2016Article
- Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT.Diagnostics (Basel, Switzerland) · 2015Article
- Lymph node staging in prostate cancer.Current urology reports · 2015Review
- Imaging active urokinase plasminogen activator in prostate cancer.Cancer research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this retrospective analysis we assessed the role of [(18)F]-FACBC-PET/CT in the prostatic cancer staging. PROCEDURE: 30 first [(18)F]-FACBC-PET/CT images of 26 patients (68.1 ± 5.8 years) were analyzed. PET/CT findings were compared with PSA concentrations, with PSA doubling times (PDT), and with correlative imaging.
resultsOn 16 [(18)F]-FACBC (53.3%) scans, 58 metabolically active lesions were found. 12 (20.7%) lesions corresponding to the local relapse were found in prostate/prostate bed and seminal vesicles, 9 (15.5%) lesions were located in regional lymph nodes, 10 (17.2%) were located in distal lymph nodes, and 26 (44.8%) metabolically active lesions were found in the skeleton. In one case, focal uptake was found in the brain, confirmed further on MRI as meningioma. The mean S-PSA level in patients with positive [(18)F]-FACBC findings was 9.5 ± 16.9 μ g/L (0.54-69 μ g/L) and in patients with negative [(18)F]-FACBC findings was 1.96 ± 1.87 μ g/L (0.11-5.9 μ g/L), but the difference was not statistically significant. However, the PSA doubling time (PDT) in patients with positive findings was significantly shorter than PDT in patients with negative findings: 3.25 ± 2.09 months (0.3-6 months) versus 31.2 ± 22.02 months (8-84 months), P < 0.0001. There was a strong positive correlation between PSA value and number of metabolically active lesions (R = 0.74) and a negative correlation between PDT and number of metabolically active lesions (R = -0.56). There was a weak negative correlation between PDT and SUVmax (R = -0.30).
conclusionAccording to our preliminary clinical experience, [(18)F]-FACBC-PET may play a role in in vivo restaging of an active prostate cancer, especially in patients with a short S-PSA doubling time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.